



(51) International Patent Classification:

A61K 39/00 (2006.01) C07K 14/725 (2006.01)
A61P 35/00 (2006.01) C07K 16/28 (2006.01)
C07K 7/02 (2006.01) C12N 5/0783 (2010.01)
C07K 7/06 (2006.01)

(21) International Application Number:

PCT/EP2021/076821

(22) International Filing Date:

29 September 2021 (29.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10 2020 125 457.1

29 September 2020 (29.09.2020) DE

63/084,963

29 September 2020 (29.09.2020) US

(71) Applicant: IMMATICS BIOTECHNOLOGIES GMBH

[DE/DE]; Paul-Ehrlich-Str. 15, 72076 Tübingen (DE).

(72) Inventors: HUKELMANN, Jens; c/o Immatics Biotechnologies GmbH, Paul-Ehrlich-Straße 15, 72076 Tübingen (DE).

SCHUSTER, Heiko; c/o Immatics Biotechnologies GmbH, Paul-Ehrlich-Straße 15, 72076 Tübingen (DE).

gen (DE). HANNEN, Ricarda; c/o Immatics Biotechnologies GmbH, Paul-Ehrlich-Straße 15, 72076 Tübingen (DE). SCHRÄDER, Christoph; c/o Immatics Biotechnologies GmbH, Paul-Ehrlich-Straße 15, 72076 Tübingen (DE). FRITSCHKE, Jens; c/o Immatics Biotechnologies GmbH, Paul-Ehrlich-Straße 15, 72076 Tübingen (DE). HOFFGAARD, Franziska; c/o Immatics Biotechnologies GmbH, Paul-Ehrlich-Straße 15, 72076 Tübingen (DE). KOWALEWSKI, Daniel; c/o Immatics Biotechnologies GmbH, Paul-Ehrlich-Straße 15, 72076 Tübingen (DE). SCHOOR, Oliver; c/o Immatics Biotechnologies GmbH, Paul-Ehrlich-Straße 15, 72076 Tübingen (DE).

(74) Agent: MICHALSKI HÜTTERMANN & PARTNER PATENTANWÄLTE MBB et al.; Speditionstraße 21, D-40221 Düsseldorf (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,

(54) Title: AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS




Fig. 1

(57) Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

12 May 2022 (12.05.2022)